The study also showed that treatment with the verteporfin, a YAP/TAZ small molecule inhibitor which functions by directly binding with the TEAD domain on the YAP protein, which disrupts the YAP/TAZ-TEAD interaction and consequently impeding the transcriptional activation of its downstream target genes crucial for tumor growth. This evidence concerns the gene YAP1 and neoplasm.